New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.
You may also be interested in...
Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
Firm presents safety, updated pivotal data at European League Against Rheumatism meeting. BLA submission for the first-in-class rheumatoid arthritis biologic was completed in March.
Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
Firm presents safety, updated pivotal data at European League Against Rheumatism meeting. BLA submission for the first-in-class rheumatoid arthritis biologic was completed in March.
Bristol Will Use Partners To Maintain Primary Care Presence
Company is using a "different model," not "exiting," primary care, CEO says. Deal with Merck for diabetes compound is example of how Bristol will use partnerships going forward.